Home » Topics » BioWorld Science

BioWorld Science
RSS

Novel fibrinogen antagonist from Merck & Co.

June 11, 1997

Eclipse cleared by FDA to begin clinical trials of PTMR

June 10, 1997

Retinal protein reduces need for standard drugs in uveitis

June 10, 1997

Pfizer terminates E5 marketing agreement

June 10, 1997

Physostigmine improves working memory and alters neural activity in volunteers

June 10, 1997

Chugai MSD to market OTC famotidine in Japan

June 10, 1997

Encouraging interim data from Avicidin trial

June 10, 1997

Protein repair enzyme may be involved in seizures/neurodegenerative diseases

June 10, 1997

Peptidomimetic inhibitors of fungal NMT prepared by Searle

June 10, 1997

Synthelabo and Praecis collaborate on prostate cancer product

June 10, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...